Urology News and Research

Latest Urology News and Research

Mycobacterium could be more effective in treating superficial bladder cancer, study finds

Universitat Autònoma de Barcelona researchers have found a mycobacterium that is more effective in treating superficial bladder cancer and does not cause infections, unlike those used up to now.

6 Oct 2015

Testosterone therapy not associated with increased risk of aggressive prostate cancer: Study

A new population-based study from The University of Texas Medical Branch at Galveston showed for the first time that exposure to testosterone therapy over a five-year period was not associated with an increased risk of aggressive prostate cancer. Further, risk of high-grade prostate cancer did not increase according to the total number of testosterone injections.

5 Oct 2015

Allergan receives FDA approval to market JUVEDERM ULTRA XC for use in lips

Allergan plc, a leading global pharmaceutical company, today announced that the company has received approval from the U.S. Food and Drug Administration to market JUVEDERM ULTRA XC for injection into the lips and perioral area for lip augmentation in adults over the age of 21. JUVEDERM ULTRA XC instantly adds fullness to the lips and is the only dermal filler that has proven results lasting up to one year for lip augmentation.

1 Oct 2015

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).

30 Sep 2015

Keck School of Medicine of USC researcher wins first Hearst Fellowship

Albert D. Kim, Ph.D., a postdoctoral fellow at the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at the University of Southern California, is the first Keck School of Medicine of USC researcher to win a Hearst Fellowship for his work investigating how to turn stem cells into nephrons, the functional units of the kidney.

26 Sep 2015

TIS physicians selected as recipients of D Magazine 2015 Best Doctors in Dallas

More than 30 physicians credentialed to practice at Texas Institute for Surgery at Texas Heath Presbyterian Dallas (TIS) are recognized by D Magazine in its October issue, Best Doctors 2015.

26 Sep 2015

Allergan releases generic INVEGA (paliperidone extended-release tablets) in the U.S.

Allergan plc, a leading global pharmaceutical company, today announced that it has launched a generic version of Janssen's INVEGA (paliperidone extended-release tablets) in the U.S. Allergan is the first company to receive FDA approval for and launch a generic version of INVEGA, demonstrating the deep expertise of the Company's global generics R&D, regulatory and supply chain teams.

25 Sep 2015

Prashant Mahajan awarded $5.76 million grant to study how febrile infants can avoid invasive procedures

Prashant Mahajan, M.D., professor of Pediatrics and Emergency Medicine, chief of the Division of Emergency Medicine in the Department of Pediatrics at Wayne State University and Children's Hospital of Michigan, has been awarded a five-year, $5.76 million grant (1R01HD085233) by the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health.

23 Sep 2015

FDA approves LONSURF for treatment of patients with metastatic colorectal cancer

Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), today announced that the U.S. Food and Drug Administration approved LONSURF (trifluridine and tipiracil), formerly known as TAS-102, for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.

22 Sep 2015

Family history: The most vital risk factor for prostate cancer

Family history is the most critical risk factor for prostate cancer. Men are more at risk if they had a father or brother with prostate cancer.

22 Sep 2015

USPSTF recommendation against regular PSA screening may delay diagnosis of prostate cancer

The U.S. Preventive Services Task Force recommendation against regular prostate specific antigen (PSA) screening for prostate cancer is controversial. While it may reduce the risk of over diagnosis and overtreatment, the reduction in intermediate and high risk cancer diagnoses raises concern because of the potential for delayed diagnoses of important cancers in men who may benefit from treatment, according to investigators reporting in The Journal of Urology.

22 Sep 2015

Active surveillance ‘viable option’ for SRM management

US researchers find no significant difference in survival outcomes between patients with small renal masses who opt for active surveillance and those who choose immediate treatment.

17 Sep 2015

Coloplast announces launch of most compact catheter for men in the U.S.

Coloplast announced the U.S. launch of SpeediCath Compact Male, the most compact catheter for men, designed so users can do more. The new product is less than half the size of a standard male catheter and may be stored, carried, used and disposed of more discreetly.

15 Sep 2015

African-American men at increased risk of dying of prostate cancer than Caucasian men

African-American men are more than twice as likely to die of prostate cancer compared to Caucasian men. World renowned robotic prostate surgeon, Dr. David Samadi, encourages them to have a complete family history of prostate cancer as part of their prevention plan.

15 Sep 2015

Researchers find key cellular enzyme that could be effective drug target for urologic cancer cells

Researchers at the SUNY Upstate Medical University have found that a key cellular enzyme, c-Abl, could be an effective drug target in cancer cells for urologic cancers, such as prostate and kidney.

11 Sep 2015

Allergan settles patent litigation with Amneal related to NAMENDA XR extended release capsules

Allergan plc, today announced that its subsidiaries Forest Laboratories, LLC and Forest Laboratories Holdings, Ltd., along with Adamas Pharmaceuticals, Inc., have entered into a settlement agreement with Amneal Pharmaceuticals LLC and related companies and subsidiaries.

10 Sep 2015

Allergan enters into agreement to acquire Aquesys and its XEN45 program

Allergan plc, a leading global pharmaceutical company, and AqueSys, Inc. a private clinical stage medical device company focused on developing ocular implants that reduce intraocular pressure (IOP) associated with glaucoma, today announced that they have entered into an agreement under which Allergan will acquire AqueSys in an all-cash transaction.

4 Sep 2015

NxThera obtains FDA clearance for Rezūm System to treat BPH

NxThera, Inc., a medical device company pioneering the application of its Convective Water Vapor Energy (WAVE) platform technology to treat endourological conditions, is pleased to announce it has received FDA 510(k) clearance of the company's Rezūm System to treat BPH.

3 Sep 2015

Allergan announces positive results from AVYCAZ Phase III studies for treatment of cUTI

Allergan plc. today announced positive topline results from RECAPTURE 1 and 2, the pivotal Phase III studies evaluating the antibiotic AVYCAZ (ceftazidime-avibactam) as a treatment for adult hospitalized patients with complicated urinary tract infections (cUTI), including pyelonephritis.

2 Sep 2015

FDA approves Allergan's sNDA to update label for TEFLARO (ceftaroline fosamil)

Allergan plc today announced the U.S. Food and Drug Administration has approved the company's supplemental new drug application (sNDA) to update the label for TEFLARO (ceftaroline fosamil) for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).

2 Sep 2015

Urology News and Research

Latest Urology News and Research

Mycobacterium could be more effective in treating superficial bladder cancer, study finds

Testosterone therapy not associated with increased risk of aggressive prostate cancer: Study

Allergan receives FDA approval to market JUVEDERM ULTRA XC for use in lips

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Keck School of Medicine of USC researcher wins first Hearst Fellowship

TIS physicians selected as recipients of D Magazine 2015 Best Doctors in Dallas

Allergan releases generic INVEGA (paliperidone extended-release tablets) in the U.S.

Prashant Mahajan awarded $5.76 million grant to study how febrile infants can avoid invasive procedures

FDA approves LONSURF for treatment of patients with metastatic colorectal cancer

Family history: The most vital risk factor for prostate cancer

USPSTF recommendation against regular PSA screening may delay diagnosis of prostate cancer

Active surveillance ‘viable option’ for SRM management

Coloplast announces launch of most compact catheter for men in the U.S.

African-American men at increased risk of dying of prostate cancer than Caucasian men

Researchers find key cellular enzyme that could be effective drug target for urologic cancer cells

Allergan settles patent litigation with Amneal related to NAMENDA XR extended release capsules

Allergan enters into agreement to acquire Aquesys and its XEN45 program

NxThera obtains FDA clearance for Rezūm System to treat BPH

Allergan announces positive results from AVYCAZ Phase III studies for treatment of cUTI

FDA approves Allergan's sNDA to update label for TEFLARO (ceftaroline fosamil)

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Urology News and Research

Latest Urology News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in